• Alice Zacarin, Mathilde Strumia, Antoine Piau, and Haleh Bagheri.
• Service de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament, faculté de médecine, centre hospitalier universitaire, 31000 Toulouse, France. Electronic address: zacarin.a@chu-toulouse.fr.
• Therapie. 2020 Nov 1; 75 (6): 663-673.

ObjectiveImproving the quality of prescribing in the elderly remains a permanent concern and a major opportunity to improve patient care. The objective of this article is to propose, from updated existing lists of potentially inappropriate medication (PIM), a list of PIM adapted to the French medical practice.MethodCombination of an explicit tool: the updated EU (7) PIM list published in 2015, adapted to the French medical practice (availability of drugs and validated indications), and an implicit tool: the recommendations of French National Health Authority (HAS) and more specifically the "alerte et maîtrise de la iatrogénie" (AMI) tools.ResultsFrom 289 PIM identified in the EU(7) PIM list, 183 drugs were included in our list according to our method. Three PIM were added to the list of "questionable" PIMs in accordance with the new French recommendations. A total of 90 PIMs were removed because of their indications or their non-commercialization in France.ConclusionThis work provides an adaptation of the EU(7)PIM to the French medical practice with the guidance of the HAS recommendations. This list is intended to be easy to use for the identification of PIMs by French physicians.Copyright © 2020 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

12 keywords...

hide…